Regeneron Pharmaceuticals, Inc.
Anti-angiogenic therapy of metastatic colorectal cancer

Last updated:

Abstract:

The present invention provides methods for treating metastatic cancer comprising identifying subjects who will respond favorably to anti-VEGF therapy. According to certain aspects of the invention, subjects are identified based on their expression level of one or more predictive biomarkers. Favorable response to anti-VEGF therapy is indicated by high expression levels of certain biomarkers or by low expression levels of certain biomarkers. An exemplary predictive biomarker is VEGF-A. Also disclosed herein are prognostic biomarkers useful for identifying cancer-bearing subjects who are expected to have better relative survival outcomes.

Status:
Grant
Type:

Utility

Filling date:

21 Nov 2019

Issue date:

13 Sep 2022